Absci Corp Asset Resilience Ratio
Absci Corp asset resilience ratio. Absci Corp (ABSI) has an Asset Resilience Ratio of 34.69% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ABSI cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Absci Corp (2021–2025)
Asset resilience ratio of Absci Corp from 2021 to 2025. This chart shows how Absci Corp's Asset Resilience Ratio has changed over time. Read total liabilities of Absci Corp for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Absci Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ABSI current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $93.28 Million | 34.69% |
| Total Liquid Assets | $93.28 Million | 34.69% |
Asset Resilience Insights
- Very High Liquidity: Absci Corp maintains exceptional liquid asset reserves at 34.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Absci Corp Industry Peers by Asset Resilience Ratio
Compare Absci Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Absci Corp Asset Resilience Ratio by Year (2021–2025)
Absci Corp asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Absci Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.45% | $124.27 Million | $216.30 Million | +24.11pp |
| 2024-12-31 | 33.34% | $71.21 Million | $213.61 Million | +21.70pp |
| 2023-12-31 | 11.64% | $25.30 Million | $217.30 Million | -20.90pp |
| 2022-12-31 | 32.55% | $104.48 Million | $321.01 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $426.19 Million | -- |
About Absci Corp
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the… Read more